A practical reference on c-Met receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Burial at sea is the practice of depositing the body or scattering its ashes in an ocean or other large body of water instead of soil. The body may be disposed in a coffin, or without one. Funerary cannibalism is the practice of eating the remains. This may be done for many reasons: for example to partake of their strength, to spiritually "close the circle" by reabsorbing their life into the family or clan, to annihilate an enemy, or due to pathological mental conditions. The Yanomami have the practice of cremating the remains and then eating the ashes with banana paste. Cremation is the incineration of the remains. This practice is common amongst Hindus and is becoming increasingly common in other cultures as well. If a family member wishes, the ashes can now be turned into a gem, similar to creating synthetic diamonds. Whether cryonics constitutes a method of interment, rather than a form of medical treatment, remains under debate. See also information-theoretic death and clinical death. Excarnation is the practice of removing the flesh from the corpse without interment. The Zoroastrians have traditionally left their dead on Towers of Silence, where the flesh of the corpses is left to be devoured by vultures and other carrion-eating birds. Alternatively, it can also mean butchering the corpse by hand to remove the flesh (also referred to as "defleshing"). Gibbeting was the semi-ancient practice of publicly displaying remains of criminals. Hanging coffins are coffins placed on cliffs, found in various locations, including China and the Philippines.
== Rationale == Long-term studies like the UK Prospective Diabetes Study (UKPDS) and the Diabetes control and complications trial (DCCT) showed that intensive insulin therapy achieved blood glucose levels closer to non-diabetic people and that this was associated with reduced frequency and severity of blood vessel damage. Damage to large and small blood vessels (macro- and microvascular disease) is central to the development of complications of diabetes. This evidence convinced most physicians who specialize in diabetes care that an important goal of treatment is to make the biochemical profile of the diabetic patient (blood lipids, HbA1c, etc.) as close to the values of non-diabetic people as possible. This is especially true for young patients with many decades of life ahead.
For removal, the provider will find the cervix with a speculum and then use ring forceps to grasp the IUD strings in the vaginal cavity and then pull the IUD out. Manufacturers and other training facilities can teach IUD placement and removal.
Large farms: When a digital agriculture technology requires much upfront investment, only large farms with sufficient assets and credit access will adopt it. For example, large farms are most likely to adopt precision agriculture technologies because of high costs. Increasingly however, automated mechanization is focusing on more but smaller autonomous machines, instead of fewer but larger machines such as observed with machines that still require human control. This trend enables smaller farms to participate in digital agriculture more evenly with larger farms, as the upfront investment becomes more equal relative to the size of the farm. Digital divide: The uneven access to information and communication technologies (ICTs) may lead to uneven adoption of, and thereby uneven gains from, digital agriculture. When digital technologies require specific skills, benefits may accrue to digitally literate farmers positioned to take advantage of such opportunities. Gender: Given gender-based disparities in ICT access and the gender gap in agribusiness value chains, men seem more likely to adopt digital agriculture. Therefore, digital technologies could perpetuate gender inequalities in the agricultural sector. Unskilled labor: Advances in on-farm productivity, particularly through digitized automation and precision agriculture, may threaten low-skilled jobs. According to the OECD, agriculture will be one of the sectors most affected by automation and McKinsey Global Institute projects that automation will displace 15% of agricultural workers in Mexico and 30% in Germany.
Sources: en.wikipedia.org
ethyl The alkyl functional group derived from ethane, consisting of two carbon atoms covalently bonded to each other and fully saturated with bonds to hydrogen atoms, with the chemical formula –CH2CH3. It is a common substituent in numerous organic compounds, though it may also exist independently as an ion or radical. In IUPAC nomenclature, the presence of an ethyl substituent may be indicated with the prefix ethyl in the name of the compound, or with the abbreviation Et in chemical formulae; e.g. ethyl alcohol (ethanol), which is often written with the formula CH3CH2OH or EtOH.
25 June – Astronomers report the discovery and confirmation of two unusually low-density exoplanets, TOI-791 b and TOI-791 c, orbiting the star TOI-791 about 1,113 light-years from Earth. Detected using NASA's Transiting Exoplanet Survey Satellite, the Jupiter-sized "super-puff" planets have densities of 0.038 and 0.047 g/cm3, respectively, making them among the lowest-density giant planets known and the largest planets yet found with densities below 0.05 g/cm3. 29 June – Palaeontologists identify a fossil vertebra collected on James Ross Island in 1985 as the earliest-known dinosaur bone collected in Antarctica. The specimen, stored for 40 years in the British Antarctic Survey collections, is confirmed to be a tail bone from a titanosaur, a group of long-necked sauropod dinosaurs. The animal is estimated to have lived about 82 million years ago, during the Late Cretaceous, when Antarctica was covered in forest. 30 June – Astronomers report a revised orbit and mass for the nearby habitable zone super-Earth GJ 3378 b. Combining radial velocity data from the Habitable-zone Planet Finder, NEID, CARMENES and SPIRou spectrometers, the team finds that the planet has an orbital period of 21.45 days and a minimum mass of 2.3 Earth masses, rather than earlier estimates of 24.73 days and 5.26 Earth masses. The revision leaves the planet within the conservative liquid-water habitable zone of its red dwarf host star, increases the likelihood that it has a terrestrial composition, and suggests that it may have retained an atmosphere despite high X-ray and ultraviolet exposure.
In the 1960s, the BOR Code of Ethics and Standards of Conduct placed professional limitations on medical technologists requiring "A medical technologist will work at all times under the direction or supervision of a pathologist or other duly qualified and licensed doctor of medicine, such qualifications being determined on the basis of accepted medical ethics" and that "A medical technologist will not act as owner, co-owner, advisor or employee, or by means of any subterfuge, participate in an arrangement whereby an individual not regularly licensed to practice medicine is enabled to own or operate a laboratory of clinical pathology." In 1965, Janet Higgins, an ASCP certified medical technologist, was removed from the Board of Registry (BOR) because she was employed at a New Jersey laboratory where the director was a state-licensed bio-analytical laboratory director, but not a physician. Though New Jersey has never required the certification for employment, the technologist successfully sued ASCP under monopolistic restraint of trade to be reinstated to the registry with the Supreme Court of New Jersey finding that the "professional status conferred on plaintiff by her certificate is an interest of sufficient substance to warrant the protection of the court." The lawsuit, and the focus on pathologists over medical technologists spurred other medical technologist societies, such as the American Society for Medical Technology (ASMT) to promote the creation of their own certifying boards.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.